Description
Glifempa-Lin Tablets (30’s)
Glifempa-Lin is a combination oral antidiabetic medication containing Empagliflozin (SGLT2 inhibitor) and Linagliptin (DPP-4 inhibitor). It is used to improve glycemic control in adults with type 2 diabetes mellitus.
Key Features:
-
Dual-action formula: Empagliflozin reduces glucose reabsorption in the kidneys, while Linagliptin increases insulin secretion and decreases glucagon levels.
-
Once-daily oral dosing for simplicity and better adherence.
-
Helps in reducing HbA1c, fasting, and postprandial glucose levels.
-
Weight-neutral or mildly reducing; low risk of hypoglycemia when used alone.
-
May offer added cardiovascular and renal benefits in high-risk patients.
Indications:
-
Management of type 2 diabetes mellitus in adults as an adjunct to diet and exercise.
-
For patients inadequately controlled on either Empagliflozin or Linagliptin alone or in combination with other antidiabetic drugs.
Dosage & Administration:
-
One tablet once daily, with or without food.
-
Dosage to be individualized based on clinical response and renal function.
-
Regular blood glucose and kidney function monitoring is advised.
Precautions:
-
Not for type 1 diabetes or diabetic ketoacidosis.
-
Monitor for signs of urinary/genital infections and pancreatitis.
-
Use cautiously in renal impairment.
-
Inform healthcare provider about all medications in use.
Possible Side Effects:
-
Urinary tract or genital infections
-
Headache, nausea, or mild gastrointestinal symptoms
-
Rare: ketoacidosis or pancreatitis
-
Low risk of hypoglycemia unless combined with insulin or sulfonylureas
Storage:
-
Store below 25°C in a dry place, away from direct sunlight.
-
Keep out of reach of children.
Reviews
There are no reviews yet.